

## Hit List

Clear

Generate Collection

Print

Fwd Refs

Bkwd Refs

Generate OACS

Search Results - Record(s) 1 through 5 of 5 returned.

☐ 1. Document ID: US 6410325 B1

Using default format because multiple data bases are involved.

L2: Entry 1 of 5

File: USPT

Jun 25, 2002

US-PAT-NO: 6410325

DOCUMENT-IDENTIFIER: US 6410325 B1

TITLE: Antisense modulation of phospholipase A2, group VI (Ca<sup>2+</sup>-independent) expression

DATE-ISSUED: June 25, 2002

## INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Bennett; C. Frank	Carlsbad	CA		
Freier; Susan M.	San Diego	CA		
Watt; Andrew T.	Vista	CA		

US-CL-CURRENT: 435/375; 435/366, 435/6, 435/91.1, 536/23.1, 536/24.31, 536/24.33, 536/24.5

Full	Title	Citation	Front	Review	Classification	Date	Reference	Abstract	Claims	Drawings
------	-------	----------	-------	--------	----------------	------	-----------	----------	--------	----------

☐ 2. Document ID: US 6183739 B1

L2: Entry 2 of 5

File: USPT

Feb 6, 2001

US-PAT-NO: 6183739

DOCUMENT-IDENTIFIER: US 6183739 B1

TITLE: Phospholipases in animal feed

DATE-ISSUED: February 6, 2001

## INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Beudeker; Robert Franciscus	Den Hoorn			NL
Kies; Arie Karst	Pijnacker			NL

US-CL-CURRENT: 424/94.6; 424/442, 426/635, 435/197, 800/298

Full	Title	Citation	Front	Review	Classification	Date	Reference			Claims	RMIC	Draw. Ds
------	-------	----------	-------	--------	----------------	------	-----------	--	--	--------	------	----------

☐ 3. Document ID: US 6017530 A

L2: Entry 3 of 5

File: USPT

Jan 25, 2000

US-PAT-NO: 6017530

DOCUMENT-IDENTIFIER: US 6017530 A

TITLE: Phospholipases in animal feed

DATE-ISSUED: January 25, 2000

## INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Beudeker; Robert Franciscus	Den Hoorn			NL
Kies; Arie Karst	Pijnacker			NL

US-CL-CURRENT: 424/94.6; 424/442, 435/197

Full	Title	Citation	Front	Review	Classification	Date	Reference			Claims	RMIC	Draw. Ds
------	-------	----------	-------	--------	----------------	------	-----------	--	--	--------	------	----------

☐ 4. Document ID: US 6008344 A

L2: Entry 4 of 5

File: USPT

Dec 28, 1999

US-PAT-NO: 6008344

DOCUMENT-IDENTIFIER: US 6008344 A

TITLE: Antisense modulation of phospholipase A2 group IV expression

DATE-ISSUED: December 28, 1999

## INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Bennett; C. Frank	Carlsbad	CA		
Cowsert; Lex M.	Carlsbad	CA		

US-CL-CURRENT: 536/24.5; 435/325, 435/6, 435/91.1, 435/91.31, 536/23.1, 536/23.2, 536/24.3

Full	Title	Citation	Front	Review	Classification	Date	Reference			Claims	RMIC	Draw. Ds
------	-------	----------	-------	--------	----------------	------	-----------	--	--	--------	------	----------

☐ 5. Document ID: US 5308754 A

L2: Entry 5 of 5

File: USPT

May 3, 1994

US-PAT-NO: 5308754

DOCUMENT-IDENTIFIER: US 5308754 A

TITLE: Electrogenenerated luminescence in solution

DATE-ISSUED: May 3, 1994

## INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Kankare; Jouko J.	SF-20610 Turku	61		FI
Haapakka, Keijo E.	Turku			FI

US-CL-CURRENT: 435/7.4; 435/7.1, 435/968, 436/172, 436/518, 436/525, 436/805,  
436/806

Full	Title	Citation	Front	Review	Classification	Date	Reference			Claims	RMIC	Draw D
------	-------	----------	-------	--------	----------------	------	-----------	--	--	--------	------	--------

Clear	Generate Collection	Print	Fwd Refs	Bkwd Refs	Generate OACS
-------	---------------------	-------	----------	-----------	---------------

Terms	Documents
Human phospholipase A2.clm.	5

Display Format:  [Previous Page](#)[Next Page](#)[Go to Doc#](#)

## Hit List

Clear	Generate Collection	Print	Fwd Refs	Bkwd Refs
Generate OACS				

Search Results - Record(s) 1 through 4 of 4 returned.

☐ 1. Document ID: US 20020177208 A1

Using default format because multiple data bases are involved.

L7: Entry 1 of 4

File: PGPB

Nov 28, 2002

PGPUB-DOCUMENT-NUMBER: 20020177208  
PGPUB-FILING-TYPE: new  
DOCUMENT-IDENTIFIER: US 20020177208 A1

TITLE: Human phospholipase A2 protein

PUBLICATION-DATE: November 28, 2002

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Hawkins, Phillip R.	Mountain View	CA	US	
Bandman, Olga	Mountain View	CA	US	
Guegler, Karl J.	Menlo Park	CA	US	
Shah, Purvi	Sunnyvale	CA	US	
Corley, Neil C.	Mountain View	CA	US	

US-CL-CURRENT: 435/196; 435/198, 435/320.1, 435/325, 435/6, 435/69.1, 536/23.2

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	RMIC	Draw D
------	-------	----------	-------	--------	----------------	------	-----------	-----------	-------------	--------	------	--------

☐ 2. Document ID: US 6645736 B2

L7: Entry 2 of 4

File: USPT

Nov 11, 2003

US-PAT-NO: 6645736  
DOCUMENT-IDENTIFIER: US 6645736 B2

TITLE: Calcium independent cytosolic phospholipase A2/B enzymes

DATE-ISSUED: November 11, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Jones; Simon	Somerville	MA		
Tang; Jin	Canton	MA		

US-CL-CURRENT: 435/18; 435/198, 435/252.3, 435/320.1, 435/350, 435/69.2, 530/300,

536/23.2

Full	Title	Citation	Front	Review	Classification	Date	Reference			Claims	KMMC	Draw D
------	-------	----------	-------	--------	----------------	------	-----------	--	--	--------	------	--------

☐ 3. Document ID: US 6242206 B1

L7: Entry 3 of 4

File: USPT

Jun 5, 2001

US-PAT-NO: 6242206

DOCUMENT-IDENTIFIER: US 6242206 B1

TITLE: Human phospholipase A2 and related nucleic acid compounds

DATE-ISSUED: June 5, 2001

## INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Choiu; Xue-Chiou C.	Lake Bluff	IL		
Kramer; Ruth M.	Indianapolis	IN		
Pickard; Richard T.	Noblesville	IN		
Sharp; John D.	Arlington	MA		
Strifler; Beth A.	Brownsburg	IN		

US-CL-CURRENT: 435/18; 435/198, 435/252.3, 435/320.1, 435/69.2, 530/350, 536/23.2

Full	Title	Citation	Front	Review	Classification	Date	Reference			Claims	KMMC	Draw D
------	-------	----------	-------	--------	----------------	------	-----------	--	--	--------	------	--------

☐ 4. Document ID: US 6197569 B1

L7: Entry 4 of 4

File: USPT

Mar 6, 2001

US-PAT-NO: 6197569

DOCUMENT-IDENTIFIER: US 6197569 B1

TITLE: Human phospholipase A2 and related nucleic acid compounds

DATE-ISSUED: March 6, 2001

## INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Choiu; Xue-Chiou C.	Lake Bluff	IL		
Kramer; Ruth M.	Indianapolis	IN		
Pickard; Richard T.	Nobelsville	IN		
Sharp; John D.	Arlington	MA		
Strifler; Beth A.	Brownsburg	IN		

US-CL-CURRENT: 435/252.3; 435/198, 435/320.1, 530/350, 536/23.2

Full	Title	Citation	Front	Review	Classification	Date	Reference			Claims	KMMC	Draw D
------	-------	----------	-------	--------	----------------	------	-----------	--	--	--------	------	--------

## WEST Search History

[Hide Items](#)[Restore](#)[Clear](#)[Cancel](#)

DATE: Friday, October 29, 2004

<b>Hide?</b>	<b>Set Name</b>	<b>Query</b>	<b>Hit Count</b>
	<i>DB=PGPB,USPT,USOC,EPAB,JPAB,DWPI; PLUR=YES; OP=ADJ</i>		
<input type="checkbox"/>	L7	11 and 435/198.ccls.	4
<input type="checkbox"/>	L6	L5 and 14	4
<input type="checkbox"/>	L5	L4 and 435/198.ccls.	4
<input type="checkbox"/>	L4	Human phospholipase A2 and dna	98
<input type="checkbox"/>	L3	Human phospholipase A2 with dna	2
<input type="checkbox"/>	L2	Human phospholipase A2.clm.	5
<input type="checkbox"/>	L1	Human phospholipase A2	124

END OF SEARCH HISTORY

```

=> s Human phospholipase A2
L1      327 HUMAN PHOSPHOLIPASE A2

=> dup rem l1
PROCESSING COMPLETED FOR L1
L2      238 DUP REM L1 (89 DUPLICATES REMOVED)

=> s l2 and (dna or rna or nucleic acid)
      2 FILES SEARCHED...
L3      81 L2 AND (DNA OR RNA OR NUCLEIC ACID)

=> s l3 and 1990-1999/py
      5 FILES SEARCHED...
L4      28 L3 AND 1990-1999/PY

=> focus l4
PROCESSING COMPLETED FOR L4
L5      28 FOCUS L4 1-

=> d l5 1-10 ibib ab

```

SEARCHES  
FOR  
1FW

L5 ANSWER 1 OF 28 HCAPLUS COPYRIGHT 2004 ACS on STN  
 ACCESSION NUMBER: 1999:326061 HCAPLUS  
 DOCUMENT NUMBER: 131:1460  
 TITLE: Cloning and expression of **human phospholipase A2** cDNA and its potential use in the diagnosis and treatment of cancer and/or inflammation  
 INVENTOR(S): Hawkins, Phillip R.; Bandman, Olga; Guegler, Karl J.; Shah, Purvi; Corley, Neil C.  
 PATENT ASSIGNEE(S): Incyte Pharmaceuticals, Inc., USA  
 SOURCE: PCT Int. Appl., 62 pp.  
 CODEN: PIXXD2  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9924587	A2	19990520	WO 1998-US23555	19981104 <--
WO 9924587	A3	19990722		
W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, HR, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
US 6103469	A	20000815	US 1997-966317	19971107
AU 9913820	A1	19990531	AU 1999-13820	19981104 <--
US 6399301	B1	20020604	US 2000-489770	20000121
US 2002177208	A1	20021128	US 2002-124591	20020416
PRIORITY APPLN. INFO.:				
			US 1997-966317	A2 19971107
			WO 1998-US23555	W 19981104
			US 2000-489770	A3 20000121

AB This invention provides protein and cDNA sequences for a newly identified **human phospholipase A2** (PLA2), which was isolated as Incyte Clone 816403 from the ovarian tumor cDNA library. The disclosed protein has homol. with mouse and rat PLA2 and has a PLA2 active site signature sequence. Northern anal. shows that the provided protein is expressed in immortalized/cancerous cells and in inflamed tissue, and thus appears to play a role in cancer and inflammation. In one embodiment, the invention relates to the use of the provided cDNA for

detecting diseases assocd. with inappropriate PLA2 activity or levels.  
Also disclosed are methods for utilizing PLA2 antagonists in the treatment  
or prevention of cancer and inflammation.

L5 ANSWER 2 OF 28 HCAPLUS COPYRIGHT 2004 ACS on STN

ACCESSION NUMBER: 1990:402561 HCAPLUS  
DOCUMENT NUMBER: 113:2561  
TITLE: Purification of acid-stable **human phospholipase A2** (PLA2), antibodies to PLA2, and cloning and expression of PLA2-encoding **DNA**  
INVENTOR(S): Kramer, Ruth M.; Pepinsky, R. Blake; Hession, Catherine  
PATENT ASSIGNEE(S): Biogen, Inc., USA  
SOURCE: PCT Int. Appl., 83 pp.  
CODEN: PIXXD2  
DOCUMENT TYPE: Patent  
LANGUAGE: English  
FAMILY ACC. NUM. COUNT: 1  
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
-----	---	-----	-----	-----
WO 8909818	A1	19891019	WO 1989-US1418	19890411
W: AU, JP, KR				
RW: AT, BE, CH, DE, FR, GB, IT, LU, NL, SE				
AU 8935482	A1	19891103	AU 1989-35482	19890411
JP 03503843	T2	19910829	JP 1989-505010	19890411 <--
PRIORITY APPLN. INFO.:			US 1988-181893	19880415
			US 1988-219491	19880712
			WO 1989-US1418	19890411

AB Human non-pancreatic PLA2 is purified and sequenced; peptide subsequences are synthesized and antibodies raised to them; oligonucleotides complementary to the predicted gene sequence are synthesized and used to clone the PLA2 gene; and the gene is expressed in mammalian cells. The peptides, antibodies, and **DNA** sequences are useful for therapy and/or diagnosis and monitoring of inflammation and tissue injury assocd. with various diseases. PLA2 was purified from human platelets by acid extn., fast S Sepharose chromatog., Sephadex G-50 gel filtration, and reversed-phase HPLC. The gene was cloned from the GM5009 human genomic **DNA** EMBL3 phage library and expressed in CHO cells.

L5 ANSWER 3 OF 28 HCAPLUS COPYRIGHT 2004 ACS on STN

ACCESSION NUMBER: 1994:186124 HCAPLUS  
DOCUMENT NUMBER: 120:186124  
TITLE: A cDNA encoding a novel **human phospholipase A2**  
INVENTOR(S): Gross, Richard  
PATENT ASSIGNEE(S): Washington University, USA  
SOURCE: U.S., 14 pp.  
CODEN: USXXAM  
DOCUMENT TYPE: Patent  
LANGUAGE: English  
FAMILY ACC. NUM. COUNT: 1  
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
-----	---	-----	-----	-----
US 5279957	A	19940118	US 1992-876284	19920430 <--
PRIORITY APPLN. INFO.:			US 1992-876284	19920430

AB A novel **human phospholipase A2** activity, referred to as PLA2(Ca-) with novel catalytic properties is characterized and a cDNA encoding it is cloned and expressed in Escherichia coli. The enzyme catalyzes the cleavage of the sn-2 fatty acid of choline and ethanolamine glycerophospholipids through a stable acyl-enzyme



intermediate; the transesterification is strongly selective for arachidonic acid and is stimulated by calcium. Antisense oligonucleotides for modulation of expression of the gene coding for the novel polypeptide and assays for screening test compds. for their ability to inhibit phospholipase A2 activity are also described. A human placental cDNA library in .lambda.gt11 was screened with antibody to sheep platelet phospholipase A2 to obtain a partial clone that was used to recover a full-length cDNA. This cDNA was placed under control of the tac promoter and the g10L leader sequence for expression in Escherichia coli. There are three genes cross-hybridizing with the cDNA in the human genome.

L5 ANSWER 4 OF 28 HCAPLUS COPYRIGHT 2004 ACS on STN  
 ACCESSION NUMBER: 1997:599302 HCAPLUS  
 DOCUMENT NUMBER: 127:244815  
 TITLE: An endogenous **human phospholipase A2** inhibitor similar to Crotalus neutralizing factor and a cDNA encoding it  
 INVENTOR(S): Hawkins, Phillip R.; Murry, Lynn E.  
 PATENT ASSIGNEE(S): Incyte Pharmaceuticals, Inc., USA  
 SOURCE: U.S., 45 pp., Cont.-in-part of U. S. Ser. No. 644,754.  
 CODEN: USXXAM  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 5663059	A	19970902	US 1996-652859	19960523 <--
CA 2253541	AA	19971127	CA 1997-2253541	19970509 <--
WO 9744454	A2	19971127	WO 1997-US7872	19970509 <--
WO 9744454	A3	19971231		
W: AT, AU, BR, CA, CH, CN, DE, DK, ES, FI, GB, IL, JP, KZ, MX, NO, NZ, RU, SE, SG, US, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, KE, LS, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
AU 9731202	A1	19971209	AU 1997-31202	19970509 <--
EP 904372	A2	19990331	EP 1997-926432	19970509 <--
R: BE, DE, ES, FR, GB, IT, NL				
JP 2001520512	T2	20011030	JP 1997-542446	19970509
US 5811520	A	19980922	US 1997-919706	19970829 <--
US 5948626	A	19990907	US 1998-153751	19980915 <--
US 2002102684	A1	20020801	US 2001-875520	20010606
PRIORITY APPLN. INFO.:				
			US 1996-644754	A2 19960510
			US 1996-652859	A 19960523
			WO 1997-US7872	W 19970509
			US 1997-919706	A3 19970829
			US 1998-153751	A3 19980915
			US 1999-364790	B1 19990730

AB A novel endogenous human phospholipase inhibitor (GIPL) that is similar to the neutralizing factor of Crotalus liver and a cDNA encoding it is cloned from a THP-1 cell line cDNA bank. The protein, or a sense or antisense DNA for it, can be of therapeutic use in controlling levels of phospholipase A2 in the treatment of inflammatory disease (no data). Antibodies to the protein also have diagnostic and therapeutic uses and expression systems can be used to screen for agonists or antagonists of the inhibitor (no data). Cloning of the cDNA by homol. searching of sequence databases is described.

L5 ANSWER 5 OF 28 HCAPLUS COPYRIGHT 2004 ACS on STN  
 ACCESSION NUMBER: 1993:97565 HCAPLUS  
 DOCUMENT NUMBER: 118:97565  
 TITLE: **Human phospholipase A2**  
 -activating protein, immunochemical methods and

reagents and kits for diagnosis of rheumatoid arthritis, cloning of the protein gene, and antisense oligonucleotide

INVENTOR(S): Bomalaski, John S.; Clark, Mike A.; Shorr, Robert G. L.  
PATENT ASSIGNEE(S): USA  
SOURCE: PCT Int. Appl., 50 pp.  
CODEN: PIXXD2  
DOCUMENT TYPE: Patent  
LANGUAGE: English  
FAMILY ACC. NUM. COUNT: 1  
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9210756	A1	19920625	WO 1991-US9302	19911206 <--
W: AU, CA, FI, JP, KR, NO, SU				
RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LU, MC, NL, SE				
US 5294698	A	19940315	US 1990-626589	19901206 <--
AU 9191473	A1	19920708	AU 1991-91473	19911206 <--
EP 563244	A1	19931006	EP 1992-902794	19911206 <--
EP 563244	B1	20000426		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, MC, NL, SE				
JP 06503647	T2	19940421	JP 1992-502972	19911206 <--
AT 192236	E	20000515	AT 1992-902794	19911206
US 5367063	A	19941122	US 1993-147925	19931104 <--
US 5580968	A	19961203	US 1994-236410	19940502 <--
US 5786154	A	19980728	US 1995-465421	19950605 <--

PRIORITY APPLN. INFO.:  
US 1990-626589 A 19901206  
WO 1991-US9302 A 19911206  
US 1993-147925 A3 19931104  
US 1994-236410 A3 19940502

AB Methods for diagnosis of rheumatoid arthritis by detection of elevated levels of the title protein (PLAP) comprise (1) obtaining a body fluid or tissue sample; (2) contacting the sample with anti-PLAP antibody; (3) detecting the antibody, thereby indicating the presence of PLAP, whereby elevated PLAP levels (as compared to controls) are indicative of rheumatoid arthritis. Kits and reagents for rheumatoid arthritis diagnosis are also disclosed. Using an ELISA protocol, specimens from patients with rheumatoid arthritis showed an av. 4.3-fold increase in PLAP levels over healthy synovial fluid or fluid from patients with osteoarthritis. The PLAP was localized and its activity characterized. The PLAP gene was cloned, then expressed in BC3H1 cells; the PLAP cDNA nucleotide sequence, and corresponding amino acid sequence, are included. Also described are antibody prodn. using recombinant PLAP, affinity purifn. of PLAP with the antibodies, and a PLAP antisense oligonucleotide sequence. The antisense sequence abolished the induction of PLAP protein synthesis in CPAE bovine endothelial cells following leukotriene D4 treatment.

L5 ANSWER 6 OF 28 HCAPLUS COPYRIGHT 2004 ACS on STN

ACCESSION NUMBER: 1999:77781 HCAPLUS  
DOCUMENT NUMBER: 130:321999  
TITLE: Molecular characterization of cDNA for phospholipase A2-activating protein  
AUTHOR(S): Chopra, A. K.; Ribardo, D. A.; Wood, T. G.; Prusak, D. J.; Xu, X.-J.; Peterson, J. W.  
CORPORATE SOURCE: Department of Microbiology and Immunology, The University of Texas Medical Branch, Galveston, TX, 77555-1070, USA  
SOURCE: Biochimica et Biophysica Acta (1999), 1444(1), 125-130  
CODEN: BBACAQ; ISSN: 0006-3002  
PUBLISHER: Elsevier Science B.V.  
DOCUMENT TYPE: Journal

LANGUAGE: English

AB A phospholipase A2-activating protein (PLAP) cDNA was cloned and sequenced from a human monocyte cDNA library, and expressed as a histidine-tagged fusion protein. The DNA-deduced aa sequence of human PLAP was 80,826 Da; however, SDS-PAGE anal. revealed a 72-74 kDa protein which matched the size of native PLAP from human monocytes. Anti-sense plap oligonucleotide blocked cholera toxin-induced release of 3H-labeled arachidonic acid from cells, indicating a potential role for PLAP in regulating phospholipase A2 activity.

REFERENCE COUNT: 18 THERE ARE 18 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 7 OF 28 HCAPLUS COPYRIGHT 2004 ACS on STN

ACCESSION NUMBER: 1998:289111 HCAPLUS

DOCUMENT NUMBER: 129:92195

TITLE: Bacterial expression and characterization of human secretory class V phospholipase A2

AUTHOR(S): Han, Sang-Kyou; Yoon, Edward T.; Cho, Wonhwa

CORPORATE SOURCE: Department of Chemistry (M/C 111), University of Illinois at Chicago, Chicago, IL, 60607-7061, USA

SOURCE: Biochemical Journal (1998), 331(2), 353-357

CODEN: BIJOAK; ISSN: 0264-6021

PUBLISHER: Portland Press Ltd.

DOCUMENT TYPE: Journal

LANGUAGE: English

AB Mammalian secretory class V phospholipase A2 (PLA2) is a newly discovered PLA2 that is implicated in eicosanoid formation in inflammatory cells. As a first step towards understanding the structure, function and regulation of this PLA2, we constructed a bacterial expression vector for human secretory class V PLA2 (hV-PLA2), over-expressed and purified the protein, and detd. its phys. and kinetic properties. When compared with human class IIa enzyme (hIIa-PLA2), hV-PLA2 has several distinct properties. First, hV-PLA2 can catalyze the hydrolysis of phosphatidylcholine more effectively than hIIa-PLA2 by two orders of magnitude. Secondly, hV-PLA2 has much higher binding affinity and activity for compactly packed phosphatidylcholine bilayers than hIIa-PLA2. Finally, hV-PLA2 has much reduced thermal stability compared with hIIa-PLA2. These data suggest that hV-PLA2 is better suited than hIIa-PLA2 for acting on the outer cellular membrane and liberating arachidonic acid from membrane phospholipids. Also, the unusually low thermal stability of hV-PLA2 might contribute to tighter regulation of its activities in extracellular media.

REFERENCE COUNT: 27 THERE ARE 27 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 8 OF 28 HCAPLUS COPYRIGHT 2004 ACS on STN

ACCESSION NUMBER: 1994:209717 HCAPLUS

DOCUMENT NUMBER: 120:209717

TITLE: Cloning and recombinant expression of a novel human low molecular weight Ca2+-dependent phospholipase A2

AUTHOR(S): Chen, Ju; Engle, Sandra J.; Seilhamer, Jeffrey J.; Tischfield, Jay A.

CORPORATE SOURCE: Sch. Med., Indiana Univ., Indianapolis, IN, 46202, USA

SOURCE: Journal of Biological Chemistry (1994), 269(4), 2365-8

CODEN: JBCHA3; ISSN: 0021-9258

DOCUMENT TYPE: Journal

LANGUAGE: English

AB Extensive biochem. studies of phospholipase A2s (PLA2s) over the last two decades indicate that there are likely to be several distinct PLA2 genes in mammals. Here the authors report the cloning of a 1-kilobase pair cDNA encoding a novel human low mol. wt. PLA2. The cDNA appears to encode a 118-amino acid mature peptide (Mr = 13,592) preceded by a 20-residue prepeptide. The deduced amino acid sequence encodes a protein that lacks one of the seven disulfide bridges found in similar PLA2s and, therefore, represents a class of enzymes distinct from the mammalian group I and

group II enzymes. An **RNA** blot hybridized with the cDNA exhibited a putative 1.2-kilobase pair transcript in heart and, less abundantly, in lung, as well as multiple putative transcripts in placenta. When the cDNA was expressed using an Epstein-Barr virus-based vector in human 293s cells, PLA2 activity accumulated in the culture medium. Conditioned medium optimally hydrolyzed the phospholipids of [1-14C]oleate-labeled Escherichia coli at neutral to alk. pH with 10 mM or greater Ca<sup>2+</sup>. In assays done with individual substrates, L-.alpha.-1-palmitoyl-2-oleoyl phosphatidylcholine was more efficiently hydrolyzed than L-.alpha.-1-palmitoyl-2-arachidonyl phosphatidylcholine, L-.alpha.-1-palmitoyl-2-arachidonyl phosphatidylethanolamine, or L-.alpha.-1-stearoyl-2-arachidonyl phosphatidylinositol.

L5 ANSWER 9 OF 28 HCAPLUS COPYRIGHT 2004 ACS on STN

ACCESSION NUMBER: 1994:291189 HCAPLUS  
DOCUMENT NUMBER: 120:291189  
TITLE: Isolation of promoter for cytosolic phospholipase A2 (cPLA2)  
AUTHOR(S): Tay, Agnes; Maxwell, Peter; Li, ZhenGuo; Goldberg, Howard; Skorecki, Karl  
CORPORATE SOURCE: Membrane Biology Group, Division of Nephrology and Hospital For Sick Children Research Institute, University of Toronto, 555 University Ave., Toronto, M5S 1A8, Can.  
SOURCE: Biochimica et Biophysica Acta (1994), 1217(3), 345-7  
CODEN: BBACAQ; ISSN: 0006-3002  
DOCUMENT TYPE: Journal  
LANGUAGE: English

AB Cytosolic phospholipase A2 (cPLA2) releases arachidonic acid from membrane phospholipids and is believed to be the rate-limiting enzyme in the arachidonic acid pathway. The authors report herein the isolation of a 3 kb fragment of rodent genomic DNA contg. part of the first intron, the first exon and 5'-flanking sequence. The start site of transcription was mapped by 5'-rapid amplification of cDNA ends and corroborated by RNase protection assay. The gene has a TATAless promoter with no classical Sp1 binding sites or initiator element. A microsatellite series of CA repeats was noted in the 5'-flanking region of both the rodent and human promoters. Deletion constructs have been analyzed for luciferase activity and confirmed promoter activity.

L5 ANSWER 10 OF 28 HCAPLUS COPYRIGHT 2004 ACS on STN

ACCESSION NUMBER: 1990:607868 HCAPLUS  
DOCUMENT NUMBER: 113:207868  
TITLE: Determination of terbium- or europium-containing traces in biochemical assays by electroluminescence  
INVENTOR(S): Kankare, Jouko Juhani; Haapakka, Keijo Ensio  
PATENT ASSIGNEE(S): Finland  
SOURCE: Ger. Offen., 11 pp.  
CODEN: GWXXBX  
DOCUMENT TYPE: Patent  
LANGUAGE: German  
FAMILY ACC. NUM. COUNT: 2  
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
DE 3908918	A1	19891005	DE 1989-3908918	19890318 <--
DE 3908918	C2	19970925		
SE 8801011	A	19890922	SE 1988-1011	19880321 <--
SE 461117	B	19900108		
SE 461117	C	19900517		
FR 2628838	A1	19890922	FR 1989-3593	19890320 <--
FR 2628838	B1	19931224		
JP 01302144	A2	19891206	JP 1989-69150	19890320 <--

JP 07050032	B4	19950531		
GB 2217007	A1	19891018	GB 1989-6408	19890321 <--
GB 2217007	B2	19920506		

PRIORITY APPLN. INFO.: SE 1988-1011 19880321  
 OTHER SOURCE(S): MARPAT 113:207868

AB A method for detn. of Tb or Eu, by measurement of delayed luminescence after application of an elec. pulse, is useful in e.g. immunoassays and **nucleic acid** hybridization assays with very high sensitivity where these metals are used as tracers. The metal is present in the form (MZ)nLmYp [M = Tb, Eu; Z = multidentate ligand; L = coupling group; Y = cell, organelle, virus, (poly)nucleotide, protein, enzyme, antibody, drug, etc.; n .gtoreq. 1; m, p .gtoreq. 0]. Thus, the Tb complex of 4-(3-isothiocyanatobenzoyl)-2,6-bis[N,N-bis(carboxymethyl)aminomethyl]phenol (I) was prepd. in 6 steps from HCHO, di-Me iminodiacetate, 4-hydroxy-3'-nitrobenzophenone, and TbCl3. Sheep anti-**human phospholipase A2** antibody was adsorbed on an Al container (as electrode), the container was washed, incubated with a sample contg. phospholipase A2, washed, incubated with the same antibody labeled with complex I, washed, and electroluminescence was measured in the presence of K2S2O8 (as radical source) with 1-ms, 8.5-V cathodic pulses by use of a photoelectrode amplifier and a 2-channel photon counter for measurements at 0.2-10 ms after the end of the pulse (luminescence) and 10.2-20 s (background).

=> d his

(FILE 'HOME' ENTERED AT 14:41:52 ON 29 OCT 2004)

FILE 'MEDLINE, HCAPLUS, BIOSIS, BIOTECHDS, EMBASE, SCISEARCH' ENTERED AT 14:42:23 ON 29 OCT 2004

L1	327 S HUMAN PHOSPHOLIPASE A2
L2	238 DUP REM L1 (89 DUPLICATES REMOVED)
L3	81 S L2 AND (DNA OR RNA OR NUCLEIC ACID)
L4	28 S L3 AND 1990-1999/PY
L5	28 FOCUS L4 1-

=> log y

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	53.75	53.96
DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	-7.00	-7.00

STN INTERNATIONAL LOGOFF AT 14:48:34 ON 29 OCT 2004